Background. Fas/Fas ligand (FasL) system is one of the major pathways trigg
ering apoptosis that has been shown to play an important role in developmen
t and pathogenesis of various diseases including liver and gastrointestinal
diseases. Studies indicate that FasL deficiency provides a survival advant
age in mice subjected to polymicrobial sepsis. However, the extent to which
Fas/FasL contributes to organ injury during sepsis is unclear. Thus, the a
im of this study was to determine whether in vivo administration of a Fas-s
ignaling inhibitor during sepsis preserves organ Junction.
Methods. Male adult C3H/HeN mice were subjected to cecal ligation and punct
ure (CLP) or sham CLP (sham). Twelve hours after CLP, mice received either
Fas-receptor fusion protein (FasFP) (200 mug/kg body weight) or the saline
vehicle. Twenty-four hours after the onset of sepsis, cardiac output and or
gan blood flow were measured with radioactive microspheres. Plasma levels o
f alanine aminotransferase, aspartate aminotransferase, and lactate dehydro
genase were assessed as indexes of litter damage. Changes in systemic cytok
ines were measured by enzyme-linked immunosorbent assay.
Results. The data indicate that although cardiac output and organ blood flo
w in the liver, intestine, kidneys, spleen, and heart decreased markedly at
24 hours after CLP, treatment with FasFP maintained the measured hemodynam
ic parameters and improved hepatic, intestinal, and heart bloodflow (P < .0
5) and partially restored spleen and renal bloodflow. Moreover, FasFP treat
ment markedly attenuated the systemic rise in alanine aminotransferase, asp
artate aminotransferase, lactate dehydrogenase, and interleukin 10 (P < .05
).
Conclusions. These results not only indicate that there is a role for Fas/F
asL-mediated processes in the induction of organ injury but suggest that in
hibition of Fas/FasL pathway may represent a novel therapeutic modality for
maintaining organ perfusion and preventing liver injury during sepsis.